e.g. mhealth
Search Results (1 to 7 of 7 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 5 JMIR Research Protocols
- 2 JMIR Cancer
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
The development of cardiotoxicity is further exacerbated by the shared underlying risk factors for developing both cancer and cardiovascular disease, such as obesity and physical inactivity [4].
Participating in exercise rehabilitation may help to improve cardiovascular health among breast cancer survivors. Obesity, lower levels of cardiorespiratory fitness, and lower physical activity levels are known risk factors for cardiovascular disease and cancer [5-7].
JMIR Cancer 2024;10:e51536
Download Citation: END BibTex RIS
However, the extent to which it would be feasible, safe, and effective (ie, positively impact fitness outcomes) for survivors of breast cancer at risk of cardiotoxicity, given their unique needs and risk profile, is unknown.
The overall aim of this study is to determine the feasibility of the REMOTE-COR-B program, a smartphone-based telerehabilitation exercise program for survivors of breast cancer at risk of cardiotoxicity.
JMIR Res Protoc 2024;13:e53301
Download Citation: END BibTex RIS
Yet, to date, there have been no studies examining m Health for symptom-tracking for cancer-related cardiotoxicity [26]. Given the severe consequences of cardiotoxicity, there may be a role for m Health in screening for this complication and improving QOL among patients at high risk for cardiotoxicity.
As a first step to closing this gap, we sought to determine considerations for the design and implementation of an m Health symptom-tracking tool for early recognition of cardiotoxicity in patients with cancer.
JMIR Cancer 2023;9:e46481
Download Citation: END BibTex RIS
In the last decade, great attention has been paid to prevention and early detection of cardiotoxicity because heart diseases are the main nononcological cause of death in these patients [5].
Our understanding of the pathophysiology and natural history of iatrogenic cardiotoxicity remains limited, and the diagnosis is carried out frequently only when cardiovascular disease presents clinically [6].
JMIR Res Protoc 2022;11(4):e31887
Download Citation: END BibTex RIS
Many risk factors for anthracycline-induced cardiotoxicity have been identified, most notably higher cumulative anthracycline doses and younger age. However, the optimal strategy for the prevention of anthracycline-induced cardiotoxicity is unclear. Currently, dexrazoxane is the only treatment for anthracycline cardioprotection approved by the United States Food and Drug Administration and European Medicines Agency.
JMIR Res Protoc 2022;11(2):e27898
Download Citation: END BibTex RIS
Reference 36: Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicitycardiotoxicity
JMIR Res Protoc 2020;9(6):e17724
Download Citation: END BibTex RIS
A major challenge is the identification of reliable circulating biomarkers that could help diagnose and predict cardiotoxicity. Many classical biomarkers (eg, C-reactive protein, N-terminal pro-B-type natriuretic peptide, and troponin) have been shown to be potential biomarkers for cardiac damage after RT [29]. In addition, circulating inflammatory cytokines indicated tissue inflammation [30].
JMIR Res Protoc 2018;7(10):e178
Download Citation: END BibTex RIS